OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Narayan on the Mechanism of Action of Nadofaragene Firadenovec in NMIBC

April 23rd 2024

Vikram Narayan, MD, discusses the mechanism of action of nadofaragene firadenovec in patients with high-risk non–muscle invasive bladder cancer.

Dr Olson on the Potential Benefit of Lifileucel in Relapsed/Refractory Metastatic Melanoma

April 23rd 2024

Daniel Olson, MD, discusses the benefit associated with lifileucel in patients with unresectable or metastatic melanoma.

Dr Patel on the Evolving Use of Neoadjuvant PD-1 Inhibitors in CSCC

April 22nd 2024

Vishal Patel, MD, FAAD, FACMS, discusses the evolving use of neoadjuvant and adjuvant PD-1 inhibition in cutaneous squamous cell carcinoma.

Dr Coombs on the Ongoing Investigation of Quizartinib in AML

April 22nd 2024

Catherine C. Coombs, MD, discusses the efficacy of the FLT3 inhibitor quizartinib in acute myeloid leukemia.

Dr Castillo on the Rationale for Evaluating Iopofosine I 131 in Waldenström Macroglobulinemia

April 19th 2024

Jorge J. Castillo, MD, discusses the rationale for evaluating the iopofosine I 131 in Waldenström macroglobulinemia.

Dr Lenz on the Prognostic Value of HER2 Expression in mCRC

April 19th 2024

Heinz-Josef Lenz, MD, FACP, discusses the prognostic value of HER2 expression in patients with KRAS wild-type metastatic colorectal cancer.

Dr Jagannath on the Mechanism of Action of Linvoseltamab in R/R Multiple Myeloma

April 19th 2024

Sundar Jagannath, MBBS, discusses the mechanism of action and tolerability of linvoseltamab in patients with relapsed/refractory multiple myeloma.

Dr Hamid on Addressing Unmet Needs in Relapsed Melanoma With Lifileucel

April 19th 2024

Omid Hamid, MD, discusses how lifileucel may address historical unmet needs in relapsed melanoma.

Dr Roland on a Study of Neoadjuvant Immune-Checkpoint Blockade Across Sarcoma Subtypes

April 19th 2024

Christina L. Roland, MD, MS, FACS, discusses a study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma.

Dr Saxena on Shifts in Treatment With Targeted and Immune Therapies in NSCLC

April 19th 2024

Ashish Saxena, MD, PhD, discusses recent shifts in treatment with the use of targeted and immune therapies in non–small cell lung cancer.

Dr Tiwari on Optimal Treatment Sequencing in HER2+ Breast Cancer

April 19th 2024

Shruti Tiwari, MD, discusses treatment sequencing in HER2+ breast cancer, highlighting how to treat these patients when they present with CNS involvement.

Dr Kopetz on Adagrasib Plus Cetuximab in KRAS G12C+ mCRC

April 19th 2024

Scott Kopetz, MD, PhD, FACP, discusses the clinical efficacy and safety of adagrasib plus cetuximab in patients with KRAS G12C-mutated mCRC.

Dr Hoebel on Modeling Spatial Interactions to Predict Outcomes in NSCLC

April 19th 2024

Katharina Hoebel, MD, PhD discusses the efficacy of incorporating spatial interactions within predictive models, in the realm of oncology.

Dr Coombs on Disease Management Strategies in AML

April 18th 2024

Catherine C. Coombs, MD, discusses strategies for disease classification and management for patients with acute myeloid leukemia.

Dr Adjei on the Rationale for Opportunistic Salpingectomy for Ovarian Cancer Prevention

April 18th 2024

Naomi Adjei, MD, MPH, MSEd, discusses an analysis of the cost-effectiveness of opportunistic salpingectomy for the primary prevention of ovarian cancer.

Dr Kirkwood on the Evolving Treatment of Resected Melanoma

April 18th 2024

John M. Kirkwood, MD, discusses the significance of the FDA approval of adjuvant nivolumab for patients with resected stage IIB or IIC melanoma.

Dr Tannir on Unmet Needs in the Treatment of Rare Kidney Tumors

April 18th 2024

Nizar M. Tannir, MD, FACP, discusses unmet needs for patients with rare kidney tumors and how these needs may be addressed in the future.

Dr Pearse on the Current Treatment Paradigm for Relapsed/Refractory MCL

April 18th 2024

William B. Pearse, MD, discusses the current treatment paradigm for patients with relapsed/refractory mantle cell lymphoma.

Dr Olson on Toxicities Associated With Lifileucel and IL-2 in Melanoma

April 18th 2024

Daniel Olson, MD, discusses toxicities associated with lifileucel and IL-2 in patients with unresectable or metastatic melanoma.

Dr Chen on the Investigation of CDK4/6 Inhibitors in Early-Stage Breast Cancer

April 18th 2024

Nan Chen, MD, discusses the investigation of CDK4/6 inhibitors in early-stage breast cancer.